arrow_back Back to App

Increased Funding for Sickle Cell Disease Treatment and Research

This act boosts funding for programs treating and preventing complications of sickle cell disease and other inherited blood disorders. This means better access to medical care and support for research, potentially improving the quality of life for affected individuals.
Key points
Increased funding for sickle cell disease treatment programs from $4.455 million to $8.205 million annually for fiscal years 2025-2029.
Expanded program scope to include prevention and treatment of sickle cell disease complications.
Allows for grants and cooperative agreements, potentially streamlining fund distribution.
Emphasizes the need for further research into the causes and cures for heritable blood disorders.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_1796
Sponsor: Rep. James, John [R-MI-10]
Process start date: 2025-03-03
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_1796.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-03-03.

What are the main provisions?

Key points include:

  • Increased funding for sickle cell disease treatment programs from $4.455 million to $8.205 million annually for fiscal years 2025-2029.
  • Expanded program scope to include prevention and treatment of sickle cell disease complications.
  • Allows for grants and cooperative agreements, potentially streamlining fund distribution.
  • Emphasizes the need for further research into the causes and cures for heritable blood disorders.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. James, John [R-MI-10].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health